WHO adds Novo Nordisk insulin to essential medicine lists

Two of Novo Nordisk's diabetes treatments have been put on the lists of essential medicines, which is curated by the World Health Organization and comprises of medicines the organization thinks should be available and affordable for patients across the globe.

Photo: Mads Nissen

An expert committee of the World Health Organization (WHO) has expanded its lists of drugs that all patients around the globe ought to be able to receive with 20 treatments for adults and 17 for children, according to the medical media Healio.

Numerous diabetes drugs are among the new additions: Novo Nordisk's Tresiba and Levmir are accompanied by Toujeo from Sanofi, in addition to medicines' biosimilar counterparts. Jardiance, which is developed by Boehringer Ingelheim and Eli Lilly, Janssen's Invokana and Farxiga from Astrazeneca are also listed.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs